Crisugabalin for generalized anxiety disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Oct 2025: Trial started, NCT07330648
  2. 9 Jan 2026: Trial registered, NCT07330648

The trials

NCT07330648: Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder

State
Under way
Phase
Phase 2
People
216 planned
Started
10 Oct 2025
Primary completion
31 Jan 2027
Arms
Crisugabalin 80mg/day group
Results
None posted
  1. 10 Oct 2025: Trial started
  2. 9 Jan 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Crisugabalin 20mg bid.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.